KC
IBER

Kryger Capital’s Ibere Pharmaceuticals IBER Stock Holding History

Kryger Capital’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-402,232
Closed -$3.94M – 140
2022
Q2 		$3.94M Sell
402,232
-19,797
-5% -$194K 0.27% 83
2022
Q1 		$4.14M Buy
+422,029
New +$4.11M 0.24% 95

Other funds holding IBER

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Kryger Capital's IBER Position: Q3 2022 in Review

Kryger Capital sold out of Ibere Pharmaceuticals (IBER) in Q3 2022, closing a stake of 402,232 shares — an estimated $3.94M sold.

Kryger Capital first reported a position in IBER in Q1 2022 and held it in 2 quarters. The position peaked at $4.14M in Q1 2022. 48 funds tracked by Wall St. Rank hold IBER as of Q3 2022.

  • Kryger Capital reported no remaining Ibere Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Kryger Capital sold 402,232 Ibere Pharmaceuticals shares in Q3 2022, an estimated $3.94M.
  • Kryger Capital first reported a position in Ibere Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Kryger Capital's Ibere Pharmaceuticals position peaked at $4.14M in Q1 2022.
  • 48 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q3 2022.

Based on Kryger Capital's 13F filing for Q3 2022, filed 10 Nov 2022.